Results 151 to 160 of about 957 (170)

Sulbactam–durlobactam for infections caused by Acinetobacter baumannii–calcoaceticus complex – Authors' reply

The Lancet Infectious Diseases, 2023
Keith S, Kaye, Sarah M, McLeod, John P, O'Donnell, David, Altarac   +3 more
openaire   +2 more sources

Sulbactam-Durlobactam, A Novel Drug for the Treatment of Multidrug Resistant Acinetobacter baumannii Infections - A Systematic Review

Infectious Disorders - Drug Targets
Background: Sulbactam-durlobactam (SUL-DUR) has been tested in vitro for its ability to gen- erate resistance in clinical isolates of Acinetobacter species. According to prior studies, combining durlobac- tam with sulbactam causes sulbactam-resistant isolates to become more active and revert to susceptibility.
Hemasri Velmurugan, Sajitha Venkatesan, Hadush Negash Meles, Krishnapriya Neelambaram, Pugazhenthan Thangaraju   +4 more
openaire   +2 more sources

Tổng quan về thuốc kháng sinh phối hợp Sulbactam và Durlobactam

Tập san Khoa học và kỹ thuật trường Đại học Bình Dương
Sulbactam/durlobactam, là một loại thuốc kháng khuẩn phối hợp đã được chấp thuận để điềutrị các bệnh nhiễm trùng do phức hợp Acinetobacter baumannii-calcoaceticus gây ra. Việc dùng đồngthời durlobactam với sulbactam ngăn ngừa sự phân hủy sulbactam bởi β-lactamase.
Thị Thu Thuỷ Nguyễn, Lời Huỳnh
openaire   +1 more source

Acinetobacter baumannii Resistance to Sulbactam/Durlobactam: A Systematic Review

Antibiotics, 2022
Stefano di Bella, Mariagrazia Perilli, Luigi Principe   +2 more
exaly  

In Vitro Activity of Sulbactam-Durlobactam against Global Isolates of Acinetobacter baumannii - calcoaceticus Complex Collected from 2016 to 2021

Antimicrobial Agents and Chemotherapy, 2022
James Karlowsky, Alita Miller, Meredith Hackel   +2 more
exaly  

In Vitro Activity of Sulbactam–Durlobactam against Carbapenem-Resistant Acinetobacter baumannii Clinical Isolates: A Multicentre Report from Italy

Antibiotics, 2022
Stefano di Bella, Mariagrazia Perilli, Luigi Principe   +2 more
exaly  

Durlobactam, a Broad-Spectrum Serine β-lactamase Inhibitor, Restores Sulbactam Activity AgainstAcinetobacterSpecies

Clinical Infectious Diseases, 2023
Alita Miller, Krisztina Papp-Wallace, Sarah McLeod   +2 more
exaly  

Molecular drivers of resistance to sulbactam-durlobactam in contemporary clinical isolates ofAcinetobacter baumannii

Antimicrobial Agents and Chemotherapy, 2023
Samir Moussa, Adam Shapiro, Ramkumar Iyer   +2 more
exaly  

The Pharmacokinetics/Pharmacodynamic Relationship of Durlobactam in Combination With Sulbactam in In Vitro and In Vivo Infection Model Systems Versus Acinetobacter baumannii-calcoaceticus Complex

Clinical Infectious Diseases, 2023
John O'Donnell
exaly  

Sulbactam/Durlobactam

Clinical Therapeutics
openaire   +2 more sources